You Searched For "keytruda" and got 19 results
Sort By:
Moderna soars 24% after the drug maker posts upbeat results from cancer vaccine trial
The pharma giant said combining its cancer vaccine with Merck's Keytruda therapy reduced patients' …
Phil Rosen
We spoke with a key Merck executive about the strategy for its top cancer drug, a $7 billion powerhouse that could soon bring in more than $20 billion
The drugmaker has also tried to reach cancers that haven't responded well to other medicines with c…
Emma Court
A new kind of treatment is working better than chemotherapy in some lung cancer patients
"Immunotherapy with checkpoint inhibitors will displace chemotherapy in yet another subset of patie…
Lydia Ramsey
One crucial quote from Merck CEO Ken Frazier at an event for big-time investors in Manhattan shows the US drug giant at a crossroads
After nearly a decade of leadership by Frazier, Merck is preparing for transition at the top, thoug…
Emma Court
Here's why the drug that helped Jimmy Carter get 'cancer-free' is such a big deal
In someone with melanoma, certain proteins called PD-1 stop the immune system from doing its job an…
Lydia Ramsey
Merck climbs after announcing massive growth for its top cancer drug, which is now on pace to generate $10 billion a year
The bulk of the company's sales win came from Keytruda, a cancer treatment that uses the immune sys…
Ben Winck
2 massive drugmakers are locked in a battle over the market for cancer immunotherapy - Goldman analysts say one is pulling ahead
Last Thursday, Merck announced positive phase 3 results for its treatment of advanced or metastatic…
Charlotte Hu
Moderna pops 17% after Merck exercises option to jointly develop a personalized cancer vaccine
The move is welcomed by investors because if successful, it would help Moderna diversify its revenu…
Matthew Fox
There's a major roadblock to one of the most talked about new cancer therapies
It means finding a unique course of treatment that is tailored toward a cancer tumor's particular c…
Lydia Ramsey
Regeneron's coming late to a group of drugs that's already worth billions - here's why the company thinks it can still compete
If it turns out that finding the cancers that are driven by the immune system is key to getting imm…
Lydia Ramsey
'We are going to have lung cancer patients living longer and better:' A new kind of cancer treatment is about to change how we treat the disease
Progression-free survival - a clinical endpoint that basically means the cancer hasn't grown - was …
Lydia Ramsey
Jimmy Carter is no longer being treated for cancer - Here's why treatments like the one he used are suddenly gaining traction
In fact, roughly 30% of metastatic melanoma patients using Keytruda alone respond completely. That'…
Lydia Ramsey
Why cancer treatments like the one Jimmy Carter used are suddenly gaining traction
In fact, roughly 30% of metastatic melanoma patients using Keytruda alone respond completely. That'…
Lydia Ramsey
Bristol-Myers Squibb won't be going after a fast approval for its lung cancer drug
But not everybody responds to the PD-1 drugs. Just a quarter to a third of non-small cell lung canc…
Lydia Ramsey,Reuters
Moderna just used a personalized vaccine to treat cancer, and it could signal a major breakthrough in how we treat the disease
"Now we are an oncology company," Moderna CEO Stéphane Bancel told Insider.
Andrew Dunn
One failed study shows just how fiercely competitive a new field of cancer therapy is
Opdivo, which has already been approved to treat other forms of cancer, has been a big hit for BMS,…
Lydia Ramsey
We're in the middle of a cancer-drug-innovation gold rush - but it has one major side effect
Within immunotherapy, researchers are trying to figure out how to get more people to respond to tre…
Lydia Ramsey
The FDA just took an entirely new approach to approving a cancer drug
On Tuesday, the agency approved pembolizumab (also known as Keytruda) to treat "unresectable or met…
Lydia Ramsey
A new kind of cancer treatment works remarkably well for some patients but not others - and researchers want to know why
But even with this level of excitement, and anecdotal cases like Carter and Schoenbauer, there are …